Enlivex Ltd. is a clinical-stage biotechnology company headquartered in Ness Ziona, Israel, focused on macrophage reprogramming immunotherapy. The company's lead candidate, Allocetra (ENX-CL-02-002), is in Phase II clinical trials for treating organ dysfunction and failure caused by sepsis. A second formulation of Allocetra (ENX-CL-05-001) is advancing through Phase I/II trials for moderate knee osteoarthritis.
The company's pipeline includes three additional candidates targeting various osteoarthritis indications: 0189-22-KMC for end-stage knee osteoarthritis, 0006-24-KMC for basal thumb osteoarthritis, and ENX-CL-06-001 for psoriatic arthritis, all in Phase I/II development. Founded in 2005 and listed on Nasdaq, Enlivex operates as a preclinical to early-stage clinical enterprise with no disclosed commercial revenue streams.
Specific information regarding employee count and geographic reach beyond the Israeli headquarters is not publicly available. The company changed its legal name from Enlivex Therapeutics Ltd. to Enlivex Ltd. in February 2026.
No 10-K filings found.